Analysis of the methods of treatment of non-alcoholic fatty liver disease: focus on innovations


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review briefly summarizes all current methods of treating non-alcoholic fatty liver disease. Based on completed randomized clinical trials, the effectiveness of each group of drugs was assessed; the main contraindications and side effects of therapy with the described drugs were identified.

全文:

受限制的访问

作者简介

Larisa Tarasova

Surgut State University; Surgut Regional Clinical Hospital; I.N. Ulyanov Chuvash State University

Email: tlarisagast18@mail.ru
MD, Associate Professor at the Department of Hospital Therapy №1 with a Course of Phthisiology of the Faculty of Medicine

Yu. Tsyganova

I.N. Ulyanov Chuvash State University

E. Busalaeva

I.N. Ulyanov Chuvash State University; Postgraduate Doctors' Training Institute of the Ministry of Health of the Chuvash Republic

O. Aryamkina

Surgut State University

参考

  1. Толмачева Н.В., Маслова Ж.В., Цыганова Ю.В. Физиологогигиеническая оценка питания детей, находящихся на санаторно-курортном лечении. Современные проблемы науки и образования. 2016;3. URL: http://www.science-education. ru/ru/article/view?id=24496 (дата обращения: 18.10.2018).
  2. Прокопьева Т.Н., Николаева Л.В., Никифорова А.Н., Тарасова Л.В. Особенности микроэлементного статуса у больных неалкогольным стеатогепатитом и алкогольной болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2015;2(114):109.
  3. Толмачева Н.В., Маслова Ж.В., Колбовская Л.В. и др. Дозозависимое влияние простых сахаров на микробиоту кишечника экспериментальных животных. Современные проблемы науки и образования. 2017;5:201.
  4. Sattar N., Forrest E., Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014. 349:g4596. doi: 10.1136/bmj. g4596.
  5. Yki-Järvinen H. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and insulin Resistance. Nutrients. 2015;7(11):9127-38. doi: 10.3390/nu7115454.
  6. Бабенко А.Ю., Лаевская М.Ю. Неалкогольная жировая болезнь печени - взаимосвязи с метаболическим синдромом. РМЖ. 2018;1(i):34-40.
  7. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DiREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;6:31-44
  8. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: 10.1002/hep.29367.
  9. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. Doi: 10.1016/j. jhep.2015.11.004.
  10. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. РЖГГК. Гепатология. 2016;2:24-42
  11. Wang L., Guo J., Lu J. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget. 2016;7(24):35632-642. Doi: 10.18632/ oncotarget.9691.
  12. Лазебник Л.Б., Радченко В.Г., Голованова Е.В. и др. Неалкогольная жировая болезнь печения: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия). Терапия. 2017;3:6-23.
  13. Takahashi H., Kotani K., Tanaka K., et al. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise intervention and Related Mechanisms Front Endocrinol (Lausanne). 2018;9:588. Doi: 10.3389/ fendo.2018.00588.
  14. Romero-Gomez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017;67(4):829-46. Doi: 10.1016/j. jhep.2017.05.016.
  15. Boers I., Muskiet F.A., Berkelaar E., et al. Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: a randomized controlled pilot-study. Lipids Health Dis. 2014;13:160. doi: 10.1186/1476-511X-13-160.
  16. Tarantino G., Citro V., Finelli C. Hype or Reality: Should Patients with Metabolic Syndromerelated NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity? J. Gastrointestin. Liver Dis. 2015;24(3):359-68. URL: http://www.jgld.ro/wp/archive/y2015/n3/a 13. Doi: http://dx.doi.org/10.15403/jgld.2014.1121.243.gta.
  17. Malhotra N., Beaton M.D. Management of nonalcoholic fatty liver disease in 2015. World J. Hepatol. 2015;7(30):2962-67.
  18. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2): 367-78.
  19. Stewart K.E. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver int. 2015;35(3):936-43. doi: 10.1111/liv.12483.
  20. Singh S., Osna N.A., Kharbanda K.K. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J. Gastroenterol. 2017;23(36):6549-70. doi: 10.3748/wjg.v23.i36.6549.
  21. Подачина С.В. Метформин - коррекция инсулинорезистентности и не только. Consilium Medicum. 2014;16(4):23-6.
  22. Ефименко Н.В., Кайсинова А.С., Федорова Т.Е. и др. Неалкогольная жировая болезнь печени: современные аспекты этиопатогенеза и лечения. Вестник Авиценны. 2016;1:129-36.
  23. He X.X., Wu X.L., Chen R.P., et al. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0162368. doi: 10.1371/journal.pone.0162368.
  24. Athyros V.G., Boutari C., Stavropoulos K., et al. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr Vasc Pharmacol. 2018;16(3):246-53. doi: 10.2174/157016111566 6170621082910.
  25. Athyros V.G., Alexandrides T.K., Bilianou H., et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17-32. Doi: 10.1016/j. metabol.2017.02.014.
  26. Pastori D., Polimeni L., Baratta F., et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4-11. doi: 10.1016/j.dld.2014.07.170.
  27. Mueller M., Thorrel A., Claudel T., et al. Ursodeoxycholic acid exerts farnesoid X. receptorantagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 2015;62(6):1398-404.
  28. Oh B., Choi W.S., Park S.B., et al. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multicentre, randomised, double-blinded, placebo-controlled trial. Int J. Clin Pract. 2016;70(4):302-11. doi: 10.1111/ijcp.12790.
  29. Steinacher D., Claudel T., Trauner M. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2017;35:282-87. doi: 10.1159/000454853.
  30. Gundermann K.J., Gundermann S., Drozdzik M., Mohan Prasad V.G. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105- 17. doi: 10.2147/CEG.S96362.
  31. Dajani A.I., Abu Hammour A.M., Zakaria M.A., et al. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J. Gastroenterol. 2015;16(3-4):99-104. doi: 10.1016/j.ajg.2015.09.001.
  32. Mora S.I., García-Román J., Gomez-Ñañez I., García-Román R. Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. Eur J. Gastroenterol Hepatol. 2018;30(8):893-900. doi: 10.1097/meg.0000000000001141.
  33. Guo T., Chang L., Xiao Y., Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015. № 10(3):e0122124. doi: 10.1371/journal. pone.0122124.
  34. Ostawal A., Mocevic E., Kragh N., Xu W. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Ther. 2016;7:411-38. Doi: 10.1007/ s13300-016-0180-0.
  35. Armstrong M.J., Gaunt P., Aithal G.P., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90. doi: 10.1016/S0140-6736(15)00803-X.
  36. Armstrong M.J., Hull D., Guo K., et al. Glucagonlike peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 2016;64:399-408. doi: 10.1016/j.jhep.2015.08.038.
  37. Baumeier C., Saussenthaler S., Kammel A., et al. Hepatic DPP4 DNA Methylation Associates With Fatty Liver. Diabetes. 2017;66:25-35. doi: 10.2337/db15-1716.
  38. Cui J., Philo L., Nguyen P., et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J. Hepatol. 2016;65:369-76. doi: 10.1016/j.jhep.2016.04.021.
  39. Joy T.R., McKenzie C.A., Tirona R.G., et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J. Gastroenterol. 2017;23;141-50. doi: 10.3748/wjg. v23.i1.141.
  40. Li H., Hua J., Guo C.X., et al. Pentoxifylline inhibits liver fibrosis via hedgehog signaling pathway. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2016;36(3):372-76. doi: 10.1007/s11596-016-1594-7.
  41. Alam S., Nazmul Hasan S., Mustafa G., et al. Effect of Pentoxifylline on Histological Activity and Fibrosis of Nonalcoholic Steatohepatitis Patients: A One Year Randomized Control Trial. J. Transl. Int. Med. 2017;5(3):155-63. doi: 10.1515/jtim-2017-0021.
  42. Vos M.B., Jin R., Konomi J.V., et al. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. Pilot Feasibility Stud. 2018;4:109. doi: 10.1186/s40814-018-0306-4.
  43. Noureddin M., Zhang A., Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs. 2016;21(3):343-57. Doi :10.1080/14728214.2016.1220533.
  44. Cho Y.K. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? Clin. Mol. Hepatol. 2018;24(3): 299-301. doi: 10.3350/cmh.2018.1006.
  45. Itani T., Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes. Sci. Pract. 2018;4(5):477-82. doi: 10.1002/osp4.294.
  46. Barchetta I., Cimini F.A., Cavallo M.G. Vitamin D. Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. Nutrients. 2017;9(9):pii: E1015. doi: 10.3390/nu9091015.
  47. Eliades M., Spyrou E. Vitamin D: a new player in nonalcoholic fatty liver disease? World J. Gastroenterol. 2015;21(6):1718-727. doi: 10.3748/wjg.v21. i6.1718.
  48. Tacke F., Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;Sep 27:1-10. doi: 10.1080/17474124.2018.1530110.
  49. Mantovani A., Nascimbeni F., Lonardo A., et al. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid. 2018;28(10):1270-1284. doi: 10.1089/thy.2018.0257.
  50. Hussien N.I., El-Kerdasy H.I., Ibrahim M.E. Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin. Can. J. Physiol. Pharmacol. 2017;12:1433-41. doi: 10.1139/cjpp-2017-0070.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##